Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 2/20 | 0.37 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.36 |
| ▸ | KIT | P10721 | 2/20 | 0.36 |
| ▸ | MMP2 | P08253 | 1/20 | 0.35 |
| ▸ | MMP13 | P45452 | 1/20 | 0.35 |
| ▸ | MMP14 | P50281 | 1/20 | 0.35 |
| ▸ | TBK1 | Q9UHD2 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.33 |
| ▸ | BCR | P11274 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13953972 | 0.89 | ABL1 (0.51) | ABL1 | |
| SCHEMBL13823090 | 0.89 | ABL1 (0.38) | ABL1P4HTMKITMMP2MMP13 | |
| SCHEMBL8998696 | 0.84 | KIT (0.45) | ABL1P4HTMKITMMP2MMP13 | |
| SCHEMBL8998867 | 0.82 | ABL1 (0.40) | ABL1MMP2MMP13MMP14 | |
| SCHEMBL8999560 | 0.79 | P4HTM (0.43) | ABL1P4HTMKITALDH1A1CYP1A2 | |
| SCHEMBL8998944 | 0.79 | ABL1 (0.46) | ABL1MMP2MMP13MMP14ALDH1A1 | |
| SCHEMBL13752539 | 0.79 | P4HTM (0.41) | ABL1P4HTMKITMMP2MMP13 | |
| SCHEMBL13752516 | 0.78 | ABL1 (0.44) | ABL1MMP2MMP13MMP14 | |
| SCHEMBL13823082 | 0.78 | ABL1 (0.40) | ABL1MMP2MMP13MMP14 | |
| SCHEMBL10046824 | 0.78 | NUDT1 (0.42) | ABL1MMP2MMP13MMP14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8188095-B2 | Gyrase inhibitors and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-05-29 | — | — | US | disclosed |
| US-8034832-B2 | Gyrase inhibitors and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-10-11 | — | — | US | disclosed |
| US-20090325935-A1 | GYRASE INHIBITORS AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED | 2009-12-31 | — | — | US | disclosed |
| US-7618974-B2 | Gyrase inhibitors and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-11-17 | — | — | US | disclosed |
| US-20090176771-A1 | GYRASE INHIBITORS AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED | 2009-07-09 | — | — | US | disclosed |
| US-7495014-B2 | Gyrase inhibitors and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090176771-A1 | GYRASE INHIBITORS AND USES THEREOF | TOP1, TOP2A, TOP2B | ABL1 460/4885P4HTM 3025/4885KIT 4688/4885 |
| US-20090325935-A1 | GYRASE INHIBITORS AND USES THEREOF | TOP1, TOP2A, TOP2B | ABL1 469/4885P4HTM 3067/4885KIT 4694/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.